Kevetrin (the "flagship" CTIX compound) Summary: Simply

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2012 at 7:09 PM

Kevetrin (the "flagship" CTIX compound) Summary:

Simply put, Kevetrin is a powerful compound that has so far shown astonishing results in lab testing against multiple different strains of treatment resistant, advanced stage cancers (lung, prostate, colon, pancreatic, etc. etc.)

Kevetrin is a small molecule that is different in structure from all currently marketed cancer drugs. It is water-soluble and simple to synthesize from commercially available starting materials

Kevetrin works by doing something no other drug has ever done before, activating the P53 gene, often called "the guardian angel of the human genome" - this is a potent cancer fighting gene that is deactivated or corrupted in over 50% of all cancer cases worldwide, regardless of cancer type

It is important to note, that this is a cancer drug that is revolutionary, not evolutionary - as it is an entirely new and novel type of treatment that has never been used in this medical capacity before

Kevetrin essentially gives your body a "genetic rebuild" to a degree, re-activating the powerful P53 gene that is active and working properly in the average healthy person

Researchers have been trying to accomplish this feat for decades – spending hundreds of millions of dollars in the process – only to come up short

Kevetrin is the first known non-geno toxic cancer drug that successfully activates the P53 gene as the mechanism of action – it has demonstrated that it can finally do what researchers have failed to accomplish for so long

It is very important to remember - Kevetrin is NON-geno toxic . This drug does not harm surrounding healthy DNA

Most cancer treatments in trials today fail because of high toxicity, and this is part of what makes Kevetrin such a compelling treatment, the non-geno toxic nature of the drug

Today’s cancer treatments are still a figurative “bull in a china shop”. They come into your body, and attack cancers aggressively, however they also attack the host as well

Kevetrin works by re-building your body’s cancer “attack dog”, without harming surrounding DNA, a much more humane and advanced way of attacking the disease and not the patient

The man behind the drug, Dr Krishna Menon, is a world renowned cancer researcher who has already helped successfully bring to market multiple other billion dollar cancer drugs (Gemzar and Alimta – both multi-billion dollar drugs)

Kevetrin is set to start its already paid for phase 1 clinical trials at Harvard's Dana Farber Cancer Institute, IMO the world's premiere cancer research and treatment facility – this phase 1 trial is set to start on or around 11/1/12

Normal phase 1 trials test on healthy volunteers and test primarily for safety. Cancer trial drugs are often given to Stage 4 terminally ill patients who usually have cancers that are already resistant to all existing therapies. Since these are the patients Cellceutix is anxious to treat, positive results could springboard development to fast-track status

The way that Dana Farber has laid out the clinical trial for Kevetrin is brilliant in the respect that it offers the FDA the exact and specific data points that will make it easier fro them to justify designating Kevetrin as a “breakthrough technology” therefore accelerating trials even beyond normal “fast tracking” status

Kevetrin will also concurrently be running an already paid for combined phase 1 trial with some of Pfizer's premiere cancer drugs – as CTIX has already signed a non-disclosure agreement with Pfizer

Cellceutix is also in negotiations with one of Europe's most distinguished Leukemia research schools, for a trial that will also be paid for by the University, saving Cellceutix millions in trial costs

Also, the value of the strong Kevetrin patent (written by Dr Paul Ginsberg, the man who wrote the Claritin patent) literally covers tens of thousands of possible future chemical combinations for new drugs; a potentially very valuable proposition for multiple drug development

The CEO understands very well the potential value of Kevetrin, and has openly stated that he will not be interested in a buy out until Kevetrin has been advanced through trials far enough to generate maximum buyout value and shareholder ROI

Bottom Line : Kevetrin has the potential to become the standard next generation broad spectrum cancer treatment, and in doing so can provide transformational profits to investors that invest in the company before any further major developments

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RunVermont Revamps City Marathon, Adds Half for 2027

Straight outta Burlington, the M&T Bank Vermont City Marathon is giving its course a facelift and, get this, throwing a half marathon into the mix for 2027. It's about time they shook things up, considering how this race is supposed to be one of the most welcoming on the block. I mean, you're talking about a marathon that's practically been the crown jewel of Vermont's...

Foodsmart's Program Links Food Benefits to Health Gains

Navigating the healthcare maze isn't for the faint of heart, especially when it comes to making sure that dollars spent on food benefits actually translate to improved health. Enter Foodsmart, the foodcare powerhouse that just rolled out its Food-is-Medicine Benefits Management (FBM) program. Turning Meals into Measurable Metrics Health plans are under mounting pressure...

GoLive Streamers: A Social Media Wild Card

Stepping Boldly into the Livestreaming Arena There's a new kid in the chaotic neighborhood of social media, and it's called GoLive Streamers. Not just another aimless stroll down Content Highway, GoLive is weaving its own defining path by fostering genuine real-time interaction. Launched in April 2026, this plucky platform has quickly amassed a following of over 74,000...

Flux Expands AI Platform to Prove Engineering ROI

Navigating the AI Maze: Flux's New Pathways Ever feel like these engineering platforms speak a language of their own? Flux's latest expansion finally offers a translator that matters. It's all about decoding whether your AI investment is delivering the goods. Engineering leaders now have more than just fluffy metrics; Flux breaks down real code-based evidence to show if...

Infrared Imaging Expands with AI, SWIR: Tech Trends

Infrared Imaging: The Backbone of Future Tech Kinda wild how infrared imaging's become a hot topic in tech circles. With the market expected to jump from USD 9.2 billion in 2026 to a hefty USD 12.6 billion by 2031, averaging a 6.4% growth rate, there's plenty to chew on. Even if you ain't the analytical type, it ain't hard to spot where the money's flowing. Infrared's...

BlueCollar Backs SuiteWorld 2026 with Platinum Sponsorship

BlueCollar Cloud Aligns with SuiteWorld 2026 If you thought the construction ERP space was just a dusty office in a backlot, think again. BlueCollar Cloud is strapping on its boots and diving into the heart of SuiteWorld 2026 with a platinum sponsorship. This isn't just a walk in the park—it's a strategic power move, aligning themselves smack-dab in the middle of...

Riverside Theatre Appoints Seasoned CFO for Growth Phase

Change Is Afoot at Riverside Theatre Down in Vero Beach, amid the sun-drenched coziness of Florida’s Treasure Coast, something’s cooking that has nothing to do with sunshine: Riverside Theatre snagged itself a new Chief Financial Officer. As nonprofits go, this one’s not a backyard operation—it’s the largest independent professional theatre in the entire state....

Decision Logic Innovates with Vitals & ShiftFlow Tools

Restaurant Battlefields: The Need for Real-Time Response Running a restaurant is no walk in the park. One slip, and you're dealing with spoiled soup or crabby customers. Decision Logic reckons they've cracked the code to smoother operations with their new tools, Vitals and ShiftFlow. At heart, these products do one thing: put critical data into the hands of managers while...

Bay Crane's Bold Auction: A Strategic Fleet Update

Bay Crane's Big Move: Strategic Fleet Update through Auction Well, here's a twist that gets the pulse racing for industry folk and machinery buffs. Bay Crane Companies, a powerhouse in the crane and hauling sector, has decided to go all in on a strategic fleet update. And what better way to move that iron than with a live, no-reserve auction? They've tapped Jeff Martin...

Mattamy Homes Earns Spot as Top Workplace in Jacksonville

Jacksonville's Housing Scene Gets a Boost In a world where everyone seems bent on working down to the bone to climb some imaginary corporate ladder, here comes Jacksonville's own Mattamy Homes with a news flash—it's possible to work, live, and still smile at the end of the day. Recently, they earned themselves a coveted spot among the best workplaces in Jacksonville for...